3-MAR Stats & Data

3‑MAR appears to share aminorex‑class risks: epidemiology links aminorex exposure to drug‑induced pulmonary arterial hypertension (PAH); repeated or sustained use of aminorex‑like stimulants may elevate PAH risk in susceptible individuals. Avoid frequent or chronic use; stop and seek medical evaluation if you develop exertional shortness of breath, chest pain, or syncope in the days to weeks after use. Aminorex derivatives have produced seizures in animal studies at higher doses; seizure risk is likely increased when combined with tramadol, bupropion, or during sleep‑deprived binges. Hydration strategy should balance overheating and hyponatremia: in hot/active settings, sip roughly 250–500 mL per hour of an electrolyte beverage; avoid compulsive over‑drinking plain water. Redose spacing: wait at least 2–3 hours before considering any additional dose; avoid overnight binges because reinforcement can mask accumulating cardiovascular and neurotoxic strain. Nasal use can be highly caustic for aminorex analogues; finely crush, use small amounts, avoid repeated back‑to‑back lines, and gently rinse with isotonic saline afterwards to limit mucosal injury. Smoking/vaping freebase gives a rapid rush that strongly encourages pipe‑reloading; use pre‑measured tiny loads, let effects plateau before reconsidering, and ventilate to reduce lung irritation from hot vapour. Given the niche market, mis‑sold or mis‑identified powders are a major risk; prefer GC‑MS/FT‑IR drug‑checking when available and avoid use when analytical verification is not possible. People with a history of hypertension, heart disease, or prior stimulant‑induced chest symptoms should avoid aminorex analogues. Sleep after‑care: allow a full night’s rest, rehydrate with electrolytes, and consider non‑sedating recovery strategies first; be cautious with high benzo doses for ‘comedowns’ due to next‑day impairment and respiratory risk.